Navigation Links
Alseres Pharmaceuticals, Inc. to Address a Congressional Briefing on Paralysis Research and the Spinal Cord Injury Community at 'Working 2 Walk' in Washington, DC, April 13-15, 2008
Date:4/9/2008

ents involve known and unknown risks, uncertainties and other factors including those risks, uncertainties and factors referred to in the Company's Annual Report on Form 10-K for the year ended December 31, 2007 filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by Alseres Pharmaceuticals from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. Alseres Pharmaceuticals is providing the information in this press release as of this date and assumes no obligations to update the information in this press release.

Contact: Sharon Correia -- 508-497-2360 ext 224

scorreia@alseres.com


'/>"/>
SOURCE Alseres Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Alseres Pharmaceuticals Announces Expansion of the Cethrin(R) Acute Spinal Cord Injury (SCI) Phase I/IIA Clinical Trial
2. Alseres Pharmaceuticals Initiates the ALTROPANE(R) POET-2 Phase III Clinical Trial Program
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
5. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
8. Sucampo Pharmaceuticals, Inc. Begins Pivotal Phase III Studies of Oral Lubiprostone to Treat Opioid-Induced Bowel Dysfunction (OBD)
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
11. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 AARP Foundation today announced it has ... suffering from the severe cold weather that has gripped much ... helping those in need; so to support these emergency relief ... to $250,000, which could mean up to $500,000 in aid. ...
(Date:1/15/2014)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... approval condition to the announced tender offer for all of the ... a result of the waiver, the transaction is no longer conditional ... on January 24, 2014 following the currently scheduled expiration time, subject ...
(Date:1/15/2014)... 15, 2014  In an unprecedented effort to curb the spread of ... other transport vehicles, an advanced and portable UV germicidal lamp manufactured ... first time. In order to prevent EMS paramedics ... West Palm Beach Fire Rescue is the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2
... ST. LOUIS, Sept. 8 Stereotaxis, Inc. (Nasdaq: ... body of evidence demonstrating exceptional clinical outcomes achieved with ... ablation. At the European Cardiology Society ... led by Dr. Tamas Szili-Torok from the Erasmus Medical ...
... MASI ) today announced that its management is scheduled to ... Four Seasons Hotel in Boston on Wednesday, September 15, at ... be available on the Masimo website at www.masimo.com . ... live presentation. About Masimo Masimo (NASDAQ: ...
Cached Medicine Technology:Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients 2Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients 3Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients 4Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients 5Masimo to Present at Stifel Nicolaus 2010 Healthcare Conference 2
(Date:4/18/2014)... worst memories? How did it make you feel? According ... personal experience, such as how sad you were or ... especially when you can,t stop thinking about it. ... the context of the memories, rather than how you ... alleviate the negative effects of these memories, a new ...
(Date:4/18/2014)... lead to potential new treatments for breaking the cycle ... Fibrosis, or scarring, is a hallmark of the disease, ... lead to serious organ damage and, in some cases, ... on findings made by Swati Bhattacharyya, PhD, research assistant ... specific protein plays in promoting fibrosis. , "Our ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... review published in the April issue of Immunity ... Institute for Medical Research, says it,s time to take ... to treating sepsis, which kills millions worldwide every ... when molecules released into the bloodstream to fight an ... is necessary for maintaining good health without inflammation, ...
(Date:4/17/2014)... as 10 million older Americans suffer from depression, often ... However, new research a project that followed the ... years found that Internet use among the elderly ... 30 percent. , "That,s a very strong effect," said ... information studies and media who led the project. "And ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... Gathers Record Attendance for Annual ... ... for the Cure(R), the,world,s largest and most progressive grassroots network of ... 7-9 at the Hilton Anatole in Dallas. The three-day event,brings together ...
... chances , , THURSDAY, Feb. 7 (HealthDay News) -- Women ... becoming pregnant by up to 65 percent if they ... About 10 percent to 15 percent of couples have ... in which a woman,s egg is fertilized in a ...
... corrects flaws in existing policy; Legislation has,overwhelming support ... 7 Next week, the House,Committee on Foreign ... and Malaria Reauthorization Act of 2008 - funding ... AIDS Relief,(PEPFAR). A coalition of more than 160 ...
... cells cheat death without unwanted side effects , ... has recently been shown to protect cells in the nervous ... this regard is limited, because it also induces blood vessel ... Xuri Li and colleagues at the National Institutes of Health, ...
... Patients with a certain gene variant drank less ... without the variant while taking the medication naltrexone, ... National Institutes of Health,s 2001-2004 COMBINE (Combined Pharmacotherapies ... About 87 percent of patients with the variant ...
... First Year of Growth in Past Three Years and Fourth Consecutive ... Revenue Increase ... the innovator and leader of BioZ(R) Impedance Cardiography (ICG),technology, today reported ... for the ICG business and do not include,results for Vermed which ...
Cached Medicine News:Health News:Susan G. Komen for the Cure(R) Hosts Annual Affiliate Leadership Conference in Dallas 2Health News:Susan G. Komen for the Cure(R) Hosts Annual Affiliate Leadership Conference in Dallas 3Health News:Acupuncture May Aid In Vitro Fertilization 2Health News:Acupuncture May Aid In Vitro Fertilization 3Health News:Congress Poised to Reauthorize Legislation Aimed at Dramatic Expansion of Global HIV and AIDS Programs 2Health News:Congress Poised to Reauthorize Legislation Aimed at Dramatic Expansion of Global HIV and AIDS Programs 3Health News:JCI online early table of contents: Feb. 7, 2008 2Health News:JCI online early table of contents: Feb. 7, 2008 3Health News:JCI online early table of contents: Feb. 7, 2008 4Health News:JCI online early table of contents: Feb. 7, 2008 5Health News:JCI online early table of contents: Feb. 7, 2008 6Health News:JCI online early table of contents: Feb. 7, 2008 7Health News:JCI online early table of contents: Feb. 7, 2008 8Health News:Gene variant predicts medication response in patients with alcohol dependence 2Health News:Gene variant predicts medication response in patients with alcohol dependence 3Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 2Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 3Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 4Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 5Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 6Health News:CardioDynamics Reports Fourth Quarter and Fiscal 2007 Results with 10% Revenue Growth in 2007 7
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: